**INTRODUCTION**

Primary growth hormone resistance or growth hormone insensitivity syndrome (Laron syndrome) is an autosomal recessive disorder caused by deletions or mutations in the growth hormone receptor gene or by post receptor defects.

**AIM**

By presenting two Iraqi cases, with primary growth hormone resistance (Laron syndrome) we aim:

1. To highlight on the prevalence of this condition in Iraq, As a sample for more than twenty case detected.
2. Appeal to high health authorities and societies to help in providing and approving recombinant IGF-1 therapy for these patients.

---

**CASE REPORT**

**The first case**: A ten years and two months old female child presented, with severe growth retardation (Figures 1,2). The photos published according to consent of the families.

- **Measures**: for the first case (female), weight 11 kg, height 79 cm both they were far below the 3rd centile (Z score for height -10.6 SD). For the second case (male), his weight 10 kg, height 72 cm (Z score for height -7.6 SD). Figures 6,7,8,9.
- **Investigations**: disclosed high plasma GH levels and low IGF-1 in both cases. The rest of the investigations were normal.

---

**CASE REPORT CON.**

**Physical examination**: Both cases revealed cheerful and smart children with severe linear growth retardation. (Figures 1,2). The photos published according to consent of the families.

- **Clinical appearance**: of severe growth hormone deficiency (midfacial hypoplasia, frontal prominence, saddle nose, flat nasal bridge) High pitched voice, dental caries, and poor dentition. (Figures 3,4,5).

---

**CONCLUSIONS**

**Conclusion**: from clinical and laboratory findings are collectively consistent with primary growth hormone insensitivity (Laron Syndrome).(1,2). We conclude that:

1. Primary growth hormone resistance (insensitivity) or Laron syndrome is a very rare condition as mentioned in the literatures(1,2,3). In Iraq, more than twenty case were detected. The same observation was also found in the Arab Gulf Countries who are members in ASPED.
2. The need for concerted efforts to provide and approved use of IGF-1 therapy for these patients is a paramount. Added to that the availability of genetic study.

---

**REFERENCES**

1. Clinical and Molecular Features of Laron Syndrome, A Genetic Disorder Protecting from Cancer
   ANNA JARCKA, MARTA KOLDOZIEZ-REZPA and BEATA BIESAGA
   In Vivo July 2016, 30 (4) 375-381
2. AACE, Endocrine Practice REVIEW ARTICLES | VOLUME 21, ISSUE 12, P1395-1402, DECEMBER 01, 201
   Lessons from 50 Years of Study of Laron Syndrome
   Zvi Laron, MD, PhD(hc)
   DOI:https://doi.org/10.4158/EP13939.RA
3. Human and Medical Genetics • Genet. Mol. Biol. 42 (4) • 2019 •
   Growth Hormone insensitivity (Laron syndrome): Report of a new family and review of Brazilian patients

---

**ACKNOWLEDGEMENTS**

No Acknowledgements

---

**CONTACT INFORMATION**

Email: alialjumaili27@yahoo.com
Mobile: 00964 7901716132